New Market Study, "Colombia Pharmaceuticals & Healthcare Report Q3 2014", Has Been Published
BMI View: Revenue recorded by multinational pharmaceutical companies will continue to be constrained in Colombia over the coming years due to severe drug price cuts. Less stringent bioequivalence regulations will also undermine sale growth posted by branded generic drugmakers. However, Colombia's relatively advanced drug reimbursement system will still offer revenue-generating opportunities for multinationals in comparison with other second-tier Latin American pharmaceutical markets.
View full press release